Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joseph Sullivan, MD. [LISTEN TIME: 14 minutes]

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.

The chair of neurology at the University of South Carolina discussed findings from a study recently presented at AHS 2025 that linked migraine to autonomic dysfunction, increased risk of atrial fibrillation, and cardioembolic stroke. [WATCH TIME: 5 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the clinical utility, supporting data, and practical use cases for STS101, a newly approved nasal powder formulation of dihydroergotamine for acute migraine.

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

The neurologist and headache specialist at the Montreal Neurological Clinic spoke about a recent national survey presented at AHS 2025 that revealed insightful patient perspectives in migraine. [WATCH TIME: 5 minutes]

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]

Experts discussed the ongoing importance of awareness, funding, and early diagnosis in amyotrophic lateral sclerosis, welcoming the return of the well-known Ice Bucket Challenge. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pediatric neurology.

Clinicians reflected on the unique, patient-centered format of the ALS Nexus conference and its potential role in accelerating ALS research and promoting care collaboration. [WATCH TIME: 4 minutes]

A panel of neuromuscular experts emphasized the importance of interdisciplinary care in helping improve quality of life and outcomes among patients living with ALS. [WATCH TIME: 4 minutes]

Biogen recently launched a pivotal phase 3 trial for omaveloxolone, aiming to explore its safety and efficacy in pediatric patients with Friedreich ataxia.

Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.

Experts discussed promising developments in ALS treatment, including gene-targeted therapies, emerging biomarkers, and AI-powered tools for diagnosis and patient support. [WATCH TIME: 5 minutes]

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.

Helius Medical Technologies expands access to its PoNS device for patients with MS as Aetna joins major payers in coverage, enhancing treatment options.

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

Atogepant outperforms topiramate in migraine prevention, showcasing superior efficacy and safety in the phase 3 TEMPLE trial results.

Centessa Pharmaceuticals initiates Phase 1 study for ORX142, a novel orexin receptor agonist targeting neurological disorders, promising new treatment avenues.

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]

Recent MR analysis uncovers protein associations with neuromyelitis optica spectrum disorder, suggesting new treatment pathways and drug targets for improved management.

The chief executive officer of Restful Sleep MD emphasized the importance of tailoring pediatric sleep interventions to each family’s unique structure, values, and challenges. [WATCH TIME: 5 minutes]